← Leaderboards
Robert Frantz
Mayo Clinic
$1,516,495
Attributed
$1,516,495
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $319.5K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,516,495 · 3
By mechanism
U01$1,512,704 · 1
M01$3,791 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clostridium Perfringens Epsilon Toxin”
- Larry Zeitlin · Epicyte Pharmaceutical, Inc.$16,115,050
- Dan M Cooper · University Of California San Diego$3,604,234
- Bruce A Mc Clane · University Of Pittsburgh At Pittsburgh$3,298,974
- Alison A. Weiss · University Of Cincinnati$1,976,698
- Mark S McClain · Vanderbilt University$1,813,560
- Timothy Vartanian · Beth Israel Deaconess Medical Center$1,808,050
Research focus
Clostridium Perfringens Epsilon ToxinAcuteAlgorithmsClinical PhenotypeBehaviorAlbuminsBiologicalBiological MarkersBaseClinicBlood CapillariesBlood SpecimenBiobankCapillaryCardiacCardiac OutputCardiomyopathiesCardiopulmonaryBiopsyCatalogsBloodAcute Myocardial InfarctionClassificationComplex
Grant awards (7)
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).$319,532
U01 · FY2018 · HL · contact PI
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).$319,532
U01 · FY2017 · HL · contact PI
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).$319,532
U01 · FY2016 · HL · contact PI
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).$314,738
U01 · FY2015 · HL · contact PI
Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).$239,370
U01 · FY2014 · HL · contact PI
PULMONARY LIMITATIONS IN CHRONIC HEART FAILURE: INFLUENCE OF ACE GENOTYPE ON EXE$3,554
M01 · FY2005 · RR
SILDENAFIL ON ALVEOLAR-CAPILLARY RECRUITMENT, PULMONARY ARTERIAL PRESSURES AND E$237
M01 · FY2005 · RR